Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jun 1;6(6):e2317838.
doi: 10.1001/jamanetworkopen.2023.17838.

Effect of Aspirin vs Enoxaparin on 90-Day Mortality in Patients Undergoing Hip or Knee Arthroplasty: A Secondary Analysis of the CRISTAL Cluster Randomized Trial

Affiliations
Randomized Controlled Trial

Effect of Aspirin vs Enoxaparin on 90-Day Mortality in Patients Undergoing Hip or Knee Arthroplasty: A Secondary Analysis of the CRISTAL Cluster Randomized Trial

CRISTAL Study Group et al. JAMA Netw Open. .

Abstract

Importance: Ischemic heart disease remains the leading cause of mortality following hip and knee arthroplasty. Due to its antiplatelet and cardioprotective properties, aspirin has been proposed as an agent that could reduce mortality when used as venous thromboembolism (VTE) prophylaxis following these procedures.

Objective: To compare aspirin with enoxaparin in reducing 90-day mortality for patients undergoing hip or knee arthroplasty procedures.

Design, setting, and participants: This study was a planned secondary analysis of the CRISTAL cluster randomized, crossover, registry-nested trial performed across 31 participating hospitals in Australia between April 20, 2019, and December 18, 2020. The aim of the CRISTAL trial was to determine whether aspirin was noninferior to enoxaparin in preventing symptomatic VTE following hip or knee arthroplasty. The primary study restricted the analysis to patients undergoing total hip or knee arthroplasty for a diagnosis of osteoarthritis only. This study includes all adult patients (aged ≥18 years) undergoing any hip or knee arthroplasty procedure at participating sites during the course of the trial. Data were analyzed from June 1 to September 6, 2021.

Interventions: Hospitals were randomized to administer all patients oral aspirin (100 mg daily) or subcutaneous enoxaparin (40 mg daily) for 35 days after hip arthroplasty and 14 days after knee arthroplasty procedures.

Main outcomes and measures: The primary outcome was mortality within 90 days. The between-group difference in mortality was estimated using cluster summary methods.

Results: A total of 23 458 patients from 31 hospitals were included, with 14 156 patients allocated to aspirin (median [IQR] age, 69 [62-77] years; 7984 [56.4%] female) and 9302 patients allocated to enoxaparin (median [IQR] age, 70 [62-77] years; 5277 [56.7%] female). The mortality rate within 90 days of surgery was 1.67% in the aspirin group and 1.53% in the enoxaparin group (estimated difference, 0.04%; 95% CI, -0.05%-0.42%). For the subgroup of 21 148 patients with a nonfracture diagnosis, the mortality rate was 0.49% in the aspirin group and 0.41% in the enoxaparin group (estimated difference, 0.05%; 95% CI, -0.67% to 0.76%).

Conclusions and relevance: In this secondary analysis of a cluster randomized trial comparing aspirin with enoxaparin following hip or knee arthroplasty, there was no significant between-group difference in mortality within 90 days when either drug was used for VTE prophylaxis.

Trial registration: http://anzctr.org.au Identifier: ACTRN12618001879257.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Walter reported receiving personal fees from Matortho, Smith&Nephew, Microport, and Johnson & Johnson; grants from Johnson & Johnson; and owning equity in Matortho and Navbit outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Site and Patient Enrollment, Randomization, and Follow-up of Participating Hospitals and Patients by Treatment Allocation Group
Figure 2.
Figure 2.. Kaplan-Meier Analysis of Mortality by Allocation Group

Similar articles

Cited by

References

    1. Harris IA, Hatton A, de Steiger R, Lewis P, Graves S. Declining early mortality after hip and knee arthroplasty. ANZ J Surg. 2020;90(1-2):119-122. doi:10.1111/ans.15529 - DOI - PubMed
    1. Sidhu VS, Kelly TL, Pratt N, et al. ; CRISTAL Study Group . Effect of aspirin vs enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: the CRISTAL randomized trial. JAMA. 2022;328(8):719-727. doi:10.1001/jama.2022.13416 - DOI - PMC - PubMed
    1. Anderson DR, Dunbar M, Murnaghan J, et al. . Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med. 2018;378(8):699-707. doi:10.1056/NEJMoa1712746 - DOI - PubMed
    1. Berstock JR, Beswick AD, Lenguerrand E, Whitehouse MR, Blom AW. Mortality after total hip replacement surgery: a systematic review. Bone Joint Res. 2014;3(6):175-182. doi:10.1302/2046-3758.36.2000239 - DOI - PMC - PubMed
    1. Berstock JR, Beswick AD, López-López JA, Whitehouse MR, Blom AW. Mortality after total knee arthroplasty: a systematic review of incidence, temporal trends, and risk factors. J Bone Joint Surg Am. 2018;100(12):1064-1070. doi:10.2106/JBJS.17.00249 - DOI - PubMed

Publication types